Fig. 3
GAGE7B promotes tumor growth and angiogenesis in gastric cancer. a-c GAGE7B promoted tumor growth in vivo. The tumor nodules derived from GAGE7B overexpressing cells grew faster during the experiment, compared with that in negative control group. The mean tumor volume of the tumor nodules in GAGE7B group was 2682 ± 375 mm3, while it was 1578 ± 191 mm3 in negative control group at the end of 5th week (t-test, *P < 0.01) (a and b). Consistently, ki-67 staining verified that GAGE7B promoted gastric cancer growth in vivo (× 100, t-test, *P < 0.01) (c). d. GAGE7B induced angiogenesis in vivo. IHC was performed for CD34 staining in the tumor nodules derived from the mice. The analysis suggested that the CD34+ microvessels were more in LV-GV416-GAGE7B group than that in negative control group (× 400, t-test, *P < 0.05). e. The supernatant of LV-GV416-GAGE7B and LV-GV416-Negative control transfected gastric cancer cells was collected and then HUVEC cells were cultured with the collected supernatant for 24 h. The result of EDU assay suggested that the proliferation ability of HUVEC was enhanced in GAGE7B group (t-test, *P < 0.05)